Mex,

I suppose my hope in RVX is placed in your statement, " The hope apabetalone has over ivermectin is apabetalone is under patent hence bp could make money from it." I do think that apabetalone probably has more benefits than ivermectin given its history and targeting of  heart science, etc, etc.

This morning I just listenned to a podcast with Dr. Byram Bridle, an Associate Professor on Viral Immunology at the University of Guelph about new peer-reviewed studies that suggests there may be reasons side effects such as heart inflammation, VITT, and other serious issues may occur in those who have been vaccinated. 

I am not an anti-vaccer and personally I have been jabbed twice with the pfizer product, but this article definitely would make me think twice about recommending to young people. All this does make me wonder about the way RVX strategizes their way to glory or the glory that we all as investors would like to see. 

I would like Bear's take on the ivermectin/apabetalone/Byram Bridle relationships. I am not a scientist so as a lay person I try to digest these things from people who have gained my trust.